ClinicalTrials.gg
CompletedNCT05512377Updated Oct 14, 2026Results posted

Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder

A Phase 2 interventional study of Brigimadlin in Pancreatic Neoplasms, Solid Tumors and Biliary Tract Cancer, sponsored by Boehringer Ingelheim. Completed at 60 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

How we know

Updated Oct 14, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,850 studies in Pancreatic Neoplasms with a site in United States — 297 open to participants now, 469 under way, 25 of them phase 3. Pancreatic Neoplasms · United States.

Enrollment
348th of 1,573
99 · median 37
Started
2022
with 87 others
Phase 2
488 of 1,850
45 open now
Registered
1,546th of 1,850
by date

Among the 1,850 studies in Pancreatic Neoplasms with a site in United States, this one is the 348th largest by enrollment of the 1,573 interventional ones that give a count, is one of 88 that started in 2022, is one of 488 in phase 2, and was the 1,546th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

297 of the 1,850 studies in Pancreatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

292 more — sign in →

All 297 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,850 studies in Pancreatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.

The purpose of this study is to find out whether a medicine called BI 907828 helps people with cancer in the biliary tract, pancreas, lung, or bladder. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. All participants take BI 907828 as a tablet once every 3 weeks. Participants may continue to take BI 907828 as long as they benefit from treatment and can tolerate it. They visit the study site regularly. At the study site, doctors regularly check the size of the tumour and whether it has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Pancreatic Neoplasms
  • Solid Tumors
  • Biliary Tract Cancer
  • Lung Neoplasms
  • Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of a solid tumour which meets the criteria for an open trial cohort:

    • Cohorts 1 and 1-CN (biliary tract adenocarcinoma): Locally advanced or biliary tract adenocarcinoma (intra- and extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary cancer).Patients must have unresectable disease and have received all available conventional therapies known to confer clinical benefit for their disease based on local approved standards; or (in the opinion of the investigator) patients are unlikely to tolerate or derive benefit from appropriate standard of care therapy.
    • Cohort 2 (pancreatic ductal adenocarcinoma): Locally advanced or metastatic pancreatic ductal adenocarcinoma. Patients must have unresectable disease and have received all available conventional therapies known to confer clinical benefit for their disease based on local approved standards.
    • Cohort 3 (lung adenocarcinoma): Locally advanced or metastatic lung adenocarcinoma. Patients must have unresectable disease and have received all available conventional therapies known to confer clinical benefit for their disease based on local approved standards.
    • Cohort 4 (urothelial bladder cancer): Locally advanced or metastatic urothelial bladder cancer. Patients must have unresectable disease and have received all available conventional therapies known to confer clinical benefit for their disease based on local approved standards.
  • Written pathology report / molecular profiling report indicating Mouse double minute 2 homolog (MDM2) amplification or a copy number ≥8 and tumor protein 53 (TP53) wild-type status. This must have been confirmed with a tissue-based test. A test with liquid is not accepted.
  • Archival tissue (formalin fixed paraffin embedded [FFPE] tumour blocks or slides) must be provided for retrospective confirmation of MDM2 amplification and TP53 status.
  • Presence of at least 1 measurable target lesion according to (RECIST) version 1.1.
  • (ECOG) performance status (PS) of 0 or 1.
  • Patient must be willing to donate mandatory blood samples for the pharmacokinetics, pharmacodynamics, and biomarker analyses
  • Adequate organ function
  • All toxicities related to previous anti-cancer therapies have resolved to ≤ (CTCAE) Grade 1 prior to trial treatment administration (except for alopecia and amenorrhea / menstrual disorders which can be of any grade and peripheral neuropathy which must be ≤CTCAE Grade 2).
  • ≥3 months at the start of treatment in the opinion of the investigator.
  • Provision of signed and dated, written form (ICF) in accordance with ICH-GCP and local legislation prior to any trial-specific procedures, sampling, or analyses.
  • Male or female patients ≥18 years old at the time of signature of the ICF. Women of (WOCBP) and men able to father a child must be ready and able to use 2 medically acceptable methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly beginning at screening, during trial participation, and until 6 months and 12 days after last dose for women and 102 days after last dose for men. A list of contraception methods meeting these criteria is provided in the patient information.

Exclusion criteria

Exclusion Criteria:

  • Previous administration of brigimadlin (BI 907828) or any other MDM2-p53 or mouse double minute 4 (MDMX, MDM4)-p53 antagonist.
  • Active bleeding, significant risk of haemorrhage (e.g. previous severe gastrointestinal bleeding, previous haemorrhagic stroke at any time), or current bleeding disorder (e.g. haemophilia, von Willebrand disease).
  • Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of trial treatment or planned within 6 months after screening (e.g. hip replacement).
  • previous or concomitant in the opinion of the investigator affecting the efficacy and/or outcome of the trial.
  • Patients who must or intend to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
  • Currently enrolled in another device or drug trial.
  • Any history of, or concomitant condition that, in the opinion of the investigator, would compromise the patient's ability to comply with the trial or interfere with the evaluation of the safety and efficacy of the trial drug.
  • Patients not expected to comply with the protocol requirements or not expected to complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the patient an unreliable trial participant).

Further exclusion criteria apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Brigimadlin 45 mg: Cohort 1 (biliary tract adenocarcinoma)

    Patients with locally advanced / metastatic MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma received brigimadlin 45 milligram (mg) orally on Day 1 of each 21-day cycle. Patients continued to receive treatment with brigimadlin until disease progression (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST) or until another reason requiring termination of treatment.

    Drug: Brigimadlin

  • Experimental
    Brigimadlin 45 mg: Cohort 2 (pancreatic ductal adenocarcinoma)

    Patients with locally advanced / metastatic MDM2 amplified, TP53 wild-type pancreatic ductal adenocarcinoma received brigimadlin 45 mg orally on Day 1 of each 21-day cycle. Patients continued to receive treatment with brigimadlin until disease progression (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST) or until another reason requiring termination of treatment.

    Drug: Brigimadlin

  • Experimental
    Brigimadlin 45 mg: Cohort 3 (lung adenocarcinoma)

    Patients with locally advanced / metastatic MDM2 amplified, TP53 wild-type lung adenocarcinoma received brigimadlin 45 mg orally on Day 1 of each 21-day cycle. Patients continued to receive treatment with brigimadlin until disease progression (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST) or until another reason requiring termination of treatment.

    Drug: Brigimadlin

  • Experimental
    Brigimadlin 45 mg: Cohort 4 (urothelial bladder cancer)

    Patients with locally advanced / metastatic MDM2 amplified, TP53 wild-type urothelial bladder cancer received brigimadlin 45 mg orally on Day 1 of each 21-day cycle. Patients continued to receive treatment with brigimadlin until disease progression (PD) according to Response Evaluation Criteria in Solid Tumours (RECIST) or until another reason requiring termination of treatment.

    Drug: Brigimadlin

Interventions

  • Patients received brigimadlin 45 mg orally on Day 1 of each 21-day cycle.

    Also known as: BI 907828

06

What researchers measure

Primary outcomes

  1. Objective Response (OR)

    OR based on central independent review is reported. OR is defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.

    Time frame: From the date of treatment start until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 25.0 months.

Secondary outcomes

  1. Duration of Objective Response (DOR)

    DOR based on central independent review is reported. DOR was defined as the time from first documented confirmed objective response (OR) until the earliest date of disease progression or death among patients with confirmed objective response.

    Time frame: From first documented confirmed objective response (OR) until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 23.9 months.

  2. Progression-free Survival (PFS)

    PFS based on central independent review. PFS was defined as the time from treatment start until the earliest date of tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

    Time frame: From treatment start until the earliest date of tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs first. Up to 25.0 months.

  3. Overall Survival (OS)

    OS was defined as the time from treatment start until death from any cause.

    Time frame: From treatment start until death from any cause. Up to 28.1 months.

  4. Disease Control (DC)

    DC based on central independent review is reported. DC was defined as a best overall response of CR, PR, or stable disease (SD) where best overall response is defined according to RECIST version 1.1.

    Time frame: From the date of treatment start until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 25.0 months.

  5. Occurrence of Treatment-emergent Adverse Events (AEs) During the On-treatment Period

    Occurrence of treatment-emergent AEs during the on-treatment period is reported as count of participants with treatment-emergent AEs during the on-treatment period.

    Time frame: From first day of administration of brigimadlin until last administration of brigimadlin plus 30 days of residual effect period (REP), up to 28.4 months.

  6. Occurrence of Treatment-emergent AEs Leading to Trial Drug Discontinuation During the On-treatment Period

    Occurrence of treatment-emergent AEs leading to trial drug discontinuation during the on-treatment period is reported as count of participants with treatment-emergent AEs leading to trial drug discontinuation during the on-treatment period.

    Time frame: From first day of administration of brigimadlin until last administration of brigimadlin plus 30 days of residual effect period (REP), up to 28.4 months.

07

Results

Posted Oct 14, 2026
Limitations and caveats
As of protocol version 6.0 dated on 4th of February 2025 patient-reported outcome questionnaires (PROs) were decided to be discontinued (further details can be found under section 5.6.2 of the study protocol). Therefore, secondary outcome measures for the PROs are not applicable for results reporting.

Participant flow

This was a Phase IIa/IIb, open-label, single-arm, multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced / metastatic, Murine Double Minute 2 (MDM2) amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours.

Participant flow — Overall Study
MilestoneBrigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)
Started67101111
Treated with trial medication66101111
Completed0000
Not completed67101111
Withdrew: Other reason than listed8311
Withdrew: Withdrawal by subject7022
Withdrew: Adverse event5011
Withdrew: Clinical disease progression6311
Withdrew: Objective disease progression40466
Withdrew: Not treated1000

Outcome measures

PrimaryObjective Response (OR)

OR based on central independent review is reported. OR is defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.

Time frame:
From the date of treatment start until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 25.0 months.
Reported as:
Number · percentage of participants
Objective Response (OR)
percentage of participantsBrigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)
Objective Response (OR)18.2 (9.76 to 29.61)0.0 (0.00 to 30.85)45.5 (16.75 to 76.62)18.2 (2.28 to 51.78)
SecondaryDuration of Objective Response (DOR)

DOR based on central independent review is reported. DOR was defined as the time from first documented confirmed objective response (OR) until the earliest date of disease progression or death among patients with confirmed objective response.

Time frame:
From first documented confirmed objective response (OR) until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 23.9 months.
Reported as:
Median · months
Duration of Objective Response (DOR)
monthsBrigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)
Duration of Objective Response (DOR)8.50 (5.40 to 15.60)—9.10 (5.40 to NA)3.75 (3.00 to NA)
SecondaryProgression-free Survival (PFS)

PFS based on central independent review. PFS was defined as the time from treatment start until the earliest date of tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs first.

Time frame:
From treatment start until the earliest date of tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs first. Up to 25.0 months.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsBrigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)
Progression-free Survival (PFS)4.20 (3.00 to 5.00)1.40 (1.20 to NA)8.00 (3.00 to 14.00)3.10 (1.40 to 5.10)
SecondaryOverall Survival (OS)

OS was defined as the time from treatment start until death from any cause.

Time frame:
From treatment start until death from any cause. Up to 28.1 months.
Reported as:
Median · months
Overall Survival (OS)
monthsBrigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)
Overall Survival (OS)10.10 (6.90 to 12.30)4.30 (3.10 to 7.80)NA (6.60 to NA)5.10 (2.00 to 11.10)
SecondaryDisease Control (DC)

DC based on central independent review is reported. DC was defined as a best overall response of CR, PR, or stable disease (SD) where best overall response is defined according to RECIST version 1.1.

Time frame:
From the date of treatment start until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 25.0 months.
Reported as:
Number · percentage of participants
Disease Control (DC)
percentage of participantsBrigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)
Disease Control (DC)75.8 (63.64 to 85.46)40.0 (12.16 to 73.76)90.9 (58.72 to 99.77)54.5 (23.38 to 83.25)
SecondaryOccurrence of Treatment-emergent Adverse Events (AEs) During the On-treatment Period

Occurrence of treatment-emergent AEs during the on-treatment period is reported as count of participants with treatment-emergent AEs during the on-treatment period.

Time frame:
From first day of administration of brigimadlin until last administration of brigimadlin plus 30 days of residual effect period (REP), up to 28.4 months.
Reported as:
Count of participants · Participants
Occurrence of Treatment-emergent Adverse Events (AEs) During the On-treatment Period
ParticipantsBrigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)
Occurrence of Treatment-emergent Adverse Events (AEs) During the On-treatment Period65101111
SecondaryOccurrence of Treatment-emergent AEs Leading to Trial Drug Discontinuation During the On-treatment Period

Occurrence of treatment-emergent AEs leading to trial drug discontinuation during the on-treatment period is reported as count of participants with treatment-emergent AEs leading to trial drug discontinuation during the on-treatment period.

Time frame:
From first day of administration of brigimadlin until last administration of brigimadlin plus 30 days of residual effect period (REP), up to 28.4 months.
Reported as:
Count of participants · Participants
Occurrence of Treatment-emergent AEs Leading to Trial Drug Discontinuation During the On-treatment Period
ParticipantsBrigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)
Occurrence of Treatment-emergent AEs Leading to Trial Drug Discontinuation During the On-treatment Period4001

Adverse events

Collected over "All-Cause Mortality", "Serious Adverse Events" and "Other Adverse Events": From first day of administration of brigimadlin until last administration of brigimadlin plus 30 days of residual effect period (REP), up to 28.4 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)52/66 (78.8%)37/66 (56.1%)65/66 (98.5%)
Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)8/10 (80%)6/10 (60%)10/10 (100%)
Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)4/11 (36.4%)5/11 (45.5%)11/11 (100%)
Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)7/11 (63.6%)4/11 (36.4%)11/11 (100%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventBrigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)
Biliary tract infectionInfections and infestations2/662/100/110/11
SepsisInfections and infestations1/660/100/112/11
Platelet count decreasedInvestigations7/661/100/110/11
AnaemiaBlood and lymphatic system disorders4/661/100/110/11
Disseminated intravascular coagulationBlood and lymphatic system disorders0/661/100/110/11
PancreatitisGastrointestinal disorders1/661/100/110/11
Upper gastrointestinal haemorrhageGastrointestinal disorders0/661/100/110/11
PyrexiaGeneral disorders0/661/100/110/11
Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/661/100/111/11
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/661/101/110/11
Most frequent other events
Showing 10 of 100
Most frequent other events
EventBrigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)
AnaemiaBlood and lymphatic system disorders28/664/103/117/11
NauseaGastrointestinal disorders40/666/106/113/11
Platelet count decreasedInvestigations39/666/105/116/11
Neutrophil count decreasedInvestigations29/661/104/112/11
Decreased appetiteMetabolism and nutrition disorders25/664/103/113/11
NeutropeniaBlood and lymphatic system disorders10/661/104/112/11
Oedema peripheralGeneral disorders6/662/104/112/11
DiarrhoeaGastrointestinal disorders19/663/102/111/11
MalaiseGeneral disorders9/663/103/111/11
ThrombocytopeniaBlood and lymphatic system disorders13/660/103/112/11

Baseline characteristics

Treated Set (TS): This patient set includes all patients who were dispensed trial medication and were documented to have taken at least one dose of trial medication.

Age, Continuous
Age, Continuous(Years)Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)Total
Mean62.6 ± 10.162.9 ± 11.366.6 ± 10.970.3 ± 8.963.9 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)Total
Female3235242
Male3476956
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)Total
American Indian or Alaska Native00000
Asian4183860
Native Hawaiian or Other Pacific Islander00000
Black or African American20114
White2127232
More than one race00000
Unknown or Not Reported20002
Country of enrollment
Country of enrollment(Participants)Brigimadlin 45 mg: Cohort 1 (Biliary Tract Adenocarcinoma)Brigimadlin 45 mg: Cohort 2 (Pancreatic Ductal Adenocarcinoma)Brigimadlin 45 mg: Cohort 3 (Lung Adenocarcinoma)Brigimadlin 45 mg: Cohort 4 (Urothelial Bladder Cancer)Total
Australia20002
Belgium20103
Germany20013
Spain711110
France20002
United Kingdom10001
Japan1552123
Korea, Republic of2001728
Singapore10001
Thailand10001
Taiwan32005
United States of America1024117
Switzerland00202
08

Study locations

60 sites
  • Southern Cancer Center
    Mobile, Alabama 36608, United States
  • University of Arizona
    Tucson, Arizona 85719, United States
  • University of Southern California
    Los Angeles, California 90033-9173, United States
  • Stanford Cancer Institute
    Palo Alto, California 94305, United States
  • Providence Medical Foundation-Santa Rosa -69764
    Santa Rosa, California 95403, United States
  • Rocky Mountain Cancer Centers-Lone Tree-69498
    Lone Tree, Colorado 80124, United States
  • Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital
    Washington D.C., District of Columbia 20016, United States
  • Norton Cancer Institute, Downtown
    Louisville, Kentucky 40202, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • Nebraska Cancer Specialists-Omaha-69066
    Omaha, Nebraska 68130, United States
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island
    Mineola, New York 11501, United States
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
    New York, New York 10016, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10022, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oncology Associates of Oregon, PC
    Eugene, Oregon 97401, United States
  • Oregon Health and Sciences University
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Prince of Wales Hospital-Randwick-66496
    Randwick, New South Wales 2031, Australia
  • ICON-South Brisbane-69267
    South Brisbane, Queensland 4101, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Ordensklinikum Linz GmbH - Barmherzige Schwestern
    Linz, 4020, Austria
  • LK Wiener Neustadt
    Wiener Neustadt, 2700, Austria
  • Universitair Ziekenhuis Antwerpen
    Edegem, 2650, Belgium
  • Universitair Ziekenhuis Gent
    Ghent, 9000, Belgium
  • CTR Georges-François Leclerc
    Dijon, 21079, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Universitätsklinikum Carl Gustav Carus Dresden
    Dresden, 01307, Germany
  • Krankenhaus Nordwest, Frankfurt
    Frankfurt, 60488, Germany
  • Medizinische Hochschule Hannover
    Hanover, 30625, Germany
  • Klinikum der Universität München AÖR
    München, 81377, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • National Cancer Center Hospital East
    Chiba, Kashiwa, 277-8577, Japan
  • Kanagawa Cancer Center
    Kanagawa, Yokohama, 241-8515, Japan
  • Tohoku University Hospital
    Miyagi, Sendai, 980-8574, Japan
  • Osaka International Cancer Institute
    Osaka, Osaka, 541-8567, Japan
  • National Cancer Center Hospital
    Tokyo, Chuo-ku, 104-0045, Japan
  • Japanese Foundation for Cancer Research
    Tokyo, Koto-ku, 135-8550, Japan
  • Yamaguchi University Hospital
    Yamaguchi, Ube, 755-8505, Japan
  • King Abdul Aziz Medical City
    Riyadh, 11481, Saudi Arabia
  • National University Hospital-Singapore-42005
    Singapore, 119074, Singapore
  • Rainbow Oncology
    KwaZulu, 4126, South Africa
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital
    Seoul, 03722, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Fundación Jiménez Díaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Clinico Universitario de Valencia
    Valencia, 46010, Spain
  • University Hospital Bern
    Bern, 3010, Switzerland
  • University Hospital Geneva
    Geneva, CH-1211, Switzerland
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung City, 80756, Taiwan
  • China Medical University Hospital
    Taichung, 404327, Taiwan
  • National Taiwan University Cancer Center
    Taipei, 106, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
  • Songklanagarind Hospital
    Hat Yai, 90110, Thailand
  • Srinagarind Hospital
    Muang, 40002, Thailand
  • University College Hospital
    London, WC1E 6AG, United Kingdom
09

References and documents

Publications

  • Yoo C, Lamarca A, Choi HJ, Vogel A, Pishvaian MJ, Goyal L, Ueno M, Marten A, Teufel M, Geng L, Morizane C. Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors. Future Oncol. 2024;20(16):1069-1077. doi: 10.2217/fon-2023-0963. Epub 2024 Jan 12. PubMed 38214149 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Sep 2025, 33 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 69 industry-sponsored phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 33 months is close to that.

Counting every sponsor, half of 396 studies reached it within 57 months; a quarter within 35 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2022
First posted
Aug 23, 2022
StartActual
Dec 13, 2022
Primary completionActual
Sep 25, 2025
CompletionActual
Sep 25, 2025
Results first posted
Oct 14, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 14, 2026
Interventions
Arms added: Brigimadlin 45 mg: Cohort 1 (biliary tract adenocarcinoma)·Brigimadlin 45 mg: Cohort 2 (pancreatic ductal adenocarcinoma)·Brigimadlin 45 mg: Cohort 3 (lung adenocarcinoma)·Brigimadlin 45 mg: Cohort 4 (urothelial bladder cancer); arms removed: brigimadlin (BI 907828) treatment arm
Oct 14, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedObjective responseResponse (OR)Time frame: Up to 30 months → From the date of treatment start until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 25.0 months.
Oct 14, 2026
Documents
Secondary outcomes
6 edited
What changed in the outcomes
  • EditedDuration of objective responseObjective Response (DOR)Time frame: Up to 30 months → From first documented confirmed objective response (OR) until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 23.9 months.
  • EditedProgression-free survivalSurvival (PFS)Time frame: Up to 30 months → From treatment start until the earliest date of tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs first. Up to 25.0 months.
  • EditedOverall survivalSurvival (OS)Time frame: Up to 50 months → From treatment start until death from any cause. Up to 28.1 months.
  • EditedDisease controlControl (DC)Time frame: Up to 30 months → From the date of treatment start until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 25.0 months.
  • EditedOccurrence of treatmentTreatment-emergent adverse eventsAdverse Events (AEs) duringDuring the onOn-treatment periodPeriodTime frame: Up to 30 months → From first day of administration of brigimadlin until last administration of brigimadlin plus 30 days of residual effect period (REP), up to 28.4 months.
  • EditedOccurrence of treatmentTreatment-emergent AEs leadingLeading to trial drug discontinuation duringTrial Drug Discontinuation During the onOn-treatment periodPeriodTime frame: Up to 30 months → From first day of administration of brigimadlin until last administration of brigimadlin plus 30 days of residual effect period (REP), up to 28.4 months.
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedObjective responseResponse (OR)Time frame: Up to 30 months → From the date of treatment start until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 25.0 months.
    Secondary outcomes 6 edited
    What changed in the outcomes
    • EditedDuration of objective responseObjective Response (DOR)Time frame: Up to 30 months → From first documented confirmed objective response (OR) until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 23.9 months.
    • EditedProgression-free survivalSurvival (PFS)Time frame: Up to 30 months → From treatment start until the earliest date of tumour progression according to RECIST version 1.1 or death from any cause, whichever occurs first. Up to 25.0 months.
    • EditedOverall survivalSurvival (OS)Time frame: Up to 50 months → From treatment start until death from any cause. Up to 28.1 months.
    • EditedDisease controlControl (DC)Time frame: Up to 30 months → From the date of treatment start until the earliest date of disease progression according to RECIST version 1.1 or death. Up to 25.0 months.
    • EditedOccurrence of treatmentTreatment-emergent adverse eventsAdverse Events (AEs) duringDuring the onOn-treatment periodPeriodTime frame: Up to 30 months → From first day of administration of brigimadlin until last administration of brigimadlin plus 30 days of residual effect period (REP), up to 28.4 months.
    • EditedOccurrence of treatmentTreatment-emergent AEs leadingLeading to trial drug discontinuation duringTrial Drug Discontinuation During the onOn-treatment periodPeriodTime frame: Up to 30 months → From first day of administration of brigimadlin until last administration of brigimadlin plus 30 days of residual effect period (REP), up to 28.4 months.
    Interventions Arms added: Brigimadlin 45 mg: Cohort 1 (biliary tract adenocarcinoma)·Brigimadlin 45 mg: Cohort 2 (pancreatic ductal adenocarcinoma)·Brigimadlin 45 mg: Cohort 3 (lung adenocarcinoma)·Brigimadlin 45 mg: Cohort 4 (urothelial bladder cancer); arms removed: brigimadlin (BI 907828) treatment arm
    + 5 other changes: identifiers, verification date, design details, references and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05512377
Responsible party
Sponsor
First posted
Aug 23, 2022
Start date
Dec 13, 2022
Primary completion
Sep 25, 2025
Completion
Sep 25, 2025
Results posted
Oct 14, 2026
Last update
Oct 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brigimadlin

Start the discussion